Investigational drug · Phase 2
Eque-cel
Also called: Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed/Refractory Multiple Myeloma.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "Eque-cel"
First trial start
2026
May 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Eque-cel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Eque-cel" as an intervention, largest first.
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Pivotal-lookingActive, not recruiting
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT06464991 · 260 participants (planned) · Start Mar 27, 2024 · Primary completion Aug 2027
Drug: Equecabtagene Autoleucel Injection; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Beijing, China; Changchun, China; Chengdu, China · 41 sites in all
- A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing MyopathyNot yet recruiting
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT07752264 · 27 participants (planned) · Start Aug 15, 2026 · Primary completion Aug 15, 2030
Drug: Equecabtagene Autoleucel Injection (Eque-cel) · For: Refractory Immune-mediated Necrotizing Myopathy
Sites: Beijing, China; Zhengzhou, China; Shanghai, China · 4 sites in all
- Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL AmyloidosisNot yet recruiting
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT07055724 · 17 participants (planned) · Start Jul 2025 · Primary completion Jun 2027
Drug: Eque-cel CAR-T Therapy · For: AL Amyloidosis
Nanjing IASO Biotechnology Co., Ltd.Industry
NCT07510100 · 17 participants (planned) · Start May 10, 2026 · Primary completion Aug 31, 2029
Drug: Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel) · For: Relapsed/Refractory Multiple Myeloma
Sites: Bunkyo-ku, Japan; Shibuya-ku, Japan; tabashi City, Japan
Tongji HospitalAcademic, hospital or other
NCT06902844 · 6 participants (planned) · Start Apr 5, 2025 · Primary completion Oct 31, 2027
Drug: Equecabtagene Autoleucel Injection · For: Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN)
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Equecabtagene autoleucel as sequential therapy in a multiple myeloma patient with renal failure: a case report.
Wang Y, Cao Q, Jia Y, et al. · Front Med (Lausanne) 2026
- 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.
Vural E, Beksac M · Turk J Haematol 2026
- Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial.
Li C, Zhou K, Hu Y, et al. · JAMA Oncol 2024
- Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lin Y, Qiu L, Usmani S, et al. · Lancet Oncol 2024
Also in development for Relapsed/Refractory Multiple Myeloma
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- SG301Phase 33 trials
Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection
- BCD-248Phase 32 trials
Biocad · Relapsed/Refractory Multiple Myeloma, Myeloma Multiple
- LBL-034Phase 21 trial
Nanjing Leads Biolabs Co.,Ltd · Relapsed/Refractory Multiple Myeloma
- REGN7945Phase 21 trial
Regeneron · Relapsed/Refractory Multiple Myeloma
- SG2918Phase 21 trial
Hangzhou Sumgen Biotech Co., Ltd. · Relapsed/Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.